Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous

Exclusion Criteria

• •Absolute contraindication to receive TMP-SMX (known allergy to TMP-SMX or sulfa drugs; TMP-SMX induced thrombocytopenia)
• •Received TMP-SMX treatment in the previous month
• •Creatinine clearance \<30ml/min/m2
• •Chronic viral infection (Hepatitis C virus, Hepatitis B virus, Human immunodeficiency virus)
• •Malignant neoplasm, except for skin neoplasm
• •Primary immune deficiencies
• •Solid organ or hematopoietic stem cell transplant recipients
• •Pregnancy or Breastfeeding
• •Current active infection, except mild active infections that to the judgement of the primary investigator do not jeopardize the study outcomes (e.g. tinea).
• •Uncontrolled chronic infection (e.g. tuberculosis- intensive phase treatment), except mild active chronic infections that to the judgement of the primary investigator do not jeopardize the study outcomes (e.g. onychomycosis).
• •Controlled chronic infection, that needs to be treated or prevented with TMP-SMX.
• •Absolute Neutrophil Count \< 750/mm3, platelets \<30x10\^9/L, o hemoglobin \<7 g/dL
• •Patients receiving Methotrexate
• •Patients participating in another research study that to the judgement of the principal investigator could jeopardize the safety or efficacy of the study drug.